Nutriband Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $82.1M
- Price
- $6.75
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.12%
- Volume
- 10.2K
About
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Quick stats
Shares outstanding12.2M
Computed float3.1M
Float / shares25.9%
Cash runway (months)15.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001676047
Websitehttps://nutriband.com
AI Summary
AI-generated1/13
minorbullishother
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Nutriband CEO Gareth Sheridan published a shareholder letter marking five years since the company's October 1, 2021 Nasdaq uplisting, recapping milestones rather than announcing new financial results.
The lead product AVERSA Fentanyl has completed commercial manufacturing scale-up and received a Type C FDA meeting, with priorities now an IND filing, a Human Abuse Liability study, and a patent application that could extend protection to 2046.
The 2021 uplisting warrants (NTRBW) expired as scheduled on September 30, 2026 with no extension or repricing, which management says leaves a cleaner capital structure with no debt.